This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ICLR vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
ICLR or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
Walgreens (WBA) and VillageMD Expand Partnership in Chicago
by Zacks Equity Research
Walgreens (WBA) and VillageMD's coordinated primary care and pharmacy services are now available in Chicago.
GoodRx Holdings, Inc. (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GoodRx Holdings, Inc. (GDRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 16.67% and 1.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Alignment Healthcare (ALHC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 28.57% and 5.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ICLR or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
GoodRx Holdings, Inc. (GDRX) Soars 21.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GoodRx Holdings, Inc. (GDRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GoodRx Holdings, Inc. (GDRX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 16.67% and 1.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Teladoc's (TDOC) BetterHelp Faces FTC Hurdle, to Pay $7.8M
by Zacks Equity Research
Teladoc's (TDOC) BetterHelp business is expected to continue implementing more comprehensive privacy standards.
GoodRx Holdings, Inc. (GDRX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 40% and 3.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -33.33% and 2.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Life Time Group Holdings, Inc. (LTH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Life Time Group Holdings, Inc. (LTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Think GoodRx Holdings, Inc. (GDRX) Could Surge 97%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 97.4% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GDRX or LHCG: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GDRX vs. LHCG: Which Stock Is the Better Value Option?
GoodRx Holdings, Inc. (GDRX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 75% and 1.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.
TRxADE (MEDS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of 50% and 27.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment and Life Sciences segment's base business is expected to have driven Q4 sales.
What's in Store for Shockwave Medical (SWAV) in Q3 Earnings?
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results are likely to reflect solid performance of its IVL system across geographies.
Earnings Preview: Agiliti (AGTI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Agiliti (AGTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ModivCare (MODV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 6.62% and 9.98%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
by Zacks Equity Research
Lantheus Holdings' (LNTH) third-quarter results are likely to reflect solid top line results on the back of robust product adoption.
AMN Healthcare (AMN) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) third-quarter results are likely to reflect solid demand across all its segments.